Search

Your search keyword '"Elvin Ahmadov"' showing total 5 results
Start Over Author "Elvin Ahmadov"
5 results on '"Elvin Ahmadov"'

1. Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients

Author

Felix Dewald, Martin Pirkl, Martha Paluschinski, Joachim Kühn, Carina Elsner, Bianca Schulte, Jacqueline Knüfer, Elvin Ahmadov, Maike Schlotz, Göksu Oral, Michael Bernhard, Mark Michael, Maura Luxenburger, Marcel Andrée, Marc Tim Hennies, Wali Hafezi, Marlin Maybrit Müller, Philipp Kümpers, Joachim Risse, Clemens Kill, Randi Katrin Manegold, Ute von Frantzki, Enrico Richter, Dorian Emmert, Werner O. Monzon-Posadas, Ingo Gräff, Monika Kogej, Antonia Büning, Maximilian Baum, Finn Teipel, Babak Mochtarzadeh, Martin Wolff, Henning Gruell, Veronica Di Cristanziano, Volker Burst, Hendrik Streeck, Ulf Dittmer, Stephan Ludwig, Jörg Timm, and Florian Klein

Subjects
Science
Abstract

Abstract Determining SARS-CoV-2 immunity is critical to assess COVID-19 risk and the need for prevention and mitigation strategies. We measured SARS-CoV-2 Spike/Nucleocapsid seroprevalence and serum neutralizing activity against Wu01, BA.4/5 and BQ.1.1 in a convenience sample of 1,411 patients receiving medical treatment in the emergency departments of five university hospitals in North Rhine-Westphalia, Germany, in August/September 2022. 62% reported underlying medical conditions and 67.7% were vaccinated according to German COVID-19 vaccination recommendations (13.9% fully vaccinated, 54.3% one booster, 23.4% two boosters). We detected Spike-IgG in 95.6%, Nucleocapsid-IgG in 24.0%, and neutralization against Wu01, BA.4/5 and BQ.1.1 in 94.4%, 85.0%, and 73.8% of participants, respectively. Neutralization against BA.4/5 and BQ.1.1 was 5.6- and 23.4-fold lower compared to Wu01. Accuracy of S-IgG detection for determination of neutralizing activity against BQ.1.1 was reduced substantially. We explored previous vaccinations and infections as correlates of BQ.1.1 neutralization using multivariable and Bayesian network analyses. Given a rather moderate adherence to COVID-19 vaccination recommendations, this analysis highlights the need to improve vaccine-uptake to reduce the COVID-19 risk of immune evasive variants. The study was registered as clinical trial (DRKS00029414).

Published
2023
Full Text
View/download PDF

2. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination

Author

Robert Biesen, Florian Kurth, Jan Zernicke, Florian Klein, Jens Klotsche, Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Alexander ten Hagen, Elisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau, Fredrik Nils Albach, Elvin Ahmadov, and Leif Erik Sander

Subjects
Medicine
Abstract

Objective The level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear.Methods In this observational cohort study, neutralising serum activity against SARS-CoV-2 wild-type (Wu01) and variant of concern Omicron BA.1 and BA.2 were assessed by pseudovirus neutralisation assay before, 4 and 12 weeks after mRNA booster immunisation in 50 rheumatic patients on MTX, 26 of whom paused the medication. 44 non-immunosuppressed persons (NIP) served as control group.Results While the neutralising serum activity against SARS-CoV-2 Wu01 and Omicron variants increased 67–73 fold in the NIP after booster vaccination, the serum activity in patients receiving MTX increased only 20–23 fold. Patients who continued MTX treatment during vaccination had significantly lower neutralisation against all variants at weeks 4 and 12 compared with patients who paused MTX and the control group, except for BA.2 at week 12. Patients who paused MTX reached comparably high neutralising capacities as NIP, except for Wu01 at week 12. The duration of the MTX pause after—not before—was associated with a significantly higher neutralisation capacity against all three variants, with an optimal duration at 10 days after vaccination.Conclusion Patients pausing MTX after COVID-19 booster showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired response indicating a potentially beneficial second booster vaccination. Our data also suggest that a 1 week MTX break is sufficient if the last administration of MTX occurs 1–3 days before vaccination.

Published
2022
Full Text
View/download PDF

4. Impaired Neutralization of SARS-CoV-2 Including Omicron Variants after COVID-19 mRNA Booster Immunization under Methotrexate Therapy

Author

Elisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau, Alexander ten Hagen, Fredrik N Albach, Jan Zernicke, Elvin Ahmadov, Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Jens Klotsche, Florian Kurth, Leif Erik Sander, Gerd Burmester, Florian Klein, and Robert Biesen

Abstract

ObjectiveTo determine the immediate need for a fourth COVID-19 vaccination based on the neutralizing capacity in patients on methotrexate (MTX) therapy after mRNA booster immunization.MethodsIn this observational cohort study, neutralizing serum activity against SARS-CoV-2 wildtype (Wu01) and variant of concern (VOC) Omicron BA.1 and BA.2 were assessed by pseudovirus neutralization assay before, 4 and 12 weeks after mRNA booster immunization in 50 rheumatic patients on MTX, 26 of whom paused the medication. 44 non-immunosuppressed persons (NIP) served as control group.ResultsWhile the neutralizing serum activity against SARS-CoV-2 Wu01 and Omicron variants increased 67-to 73-fold in the NIP after booster vaccination, the serum activity in patients receiving MTX increased only 20-to 23-fold. As a result, significantly lower neutralizing capacities were measured in patients on MTX compared to the NIP at week 4. Patients who continued MTX treatment during vaccination had significantly lower neutralizing serum titres against all three virus strains at week 4 and 12 compared to patients who paused MTX and the control group, except for BA.2 at week 12. Patients who paused MTX reached comparably high neutralization titres as the NIP, except for Wu01 at week 12. Neutralization of omicron variants was significantly lower in comparison to wildtype in both groups.ConclusionPatients pausing MTX showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired booster response indicating a potential benefit of a second booster vaccination.

Published
2022
Full Text
View/download PDF

5. Pausing Methotrexate Prevents Impairment of Omicron BA.1 and BA.2 Neutralization after COVID-19 Booster Vaccination

Author

Elisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau, Jens Klotsche, Fredrik Nils Albach, Alexander ten Hagen, Jan Zernicke, Elvin Ahmadov, Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Florian Kurth, Leif Erik Sander, Gerd R Burmester, Florian Klein, and Robert Biesen

Subjects
Vaccines, History, COVID-19 Vaccines, Polymers and Plastics, SARS-CoV-2, Vaccination, Immunology, COVID-19, Industrial and Manufacturing Engineering, Methotrexate, Rheumatology, Antirheumatic Agents, Humans, Immunology and Allergy, Business and International Management
Abstract

ObjectiveThe level of neutralising capacity against Omicron BA.1 and BA.2 after third COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is unclear.MethodsIn this observational cohort study, neutralising serum activity against SARS-CoV-2 wild-type (Wu01) and variant of concern Omicron BA.1 and BA.2 were assessed by pseudovirus neutralisation assay before, 4 and 12 weeks after mRNA booster immunisation in 50 rheumatic patients on MTX, 26 of whom paused the medication. 44 non-immunosuppressed persons (NIP) served as control group.ResultsWhile the neutralising serum activity against SARS-CoV-2 Wu01 and Omicron variants increased 67–73 fold in the NIP after booster vaccination, the serum activity in patients receiving MTX increased only 20–23 fold. Patients who continued MTX treatment during vaccination had significantly lower neutralisation against all variants at weeks 4 and 12 compared with patients who paused MTX and the control group, except for BA.2 at week 12. Patients who paused MTX reached comparably high neutralising capacities as NIP, except for Wu01 at week 12. The duration of the MTX pause after—not before—was associated with a significantly higher neutralisation capacity against all three variants, with an optimal duration at 10 days after vaccination.ConclusionPatients pausing MTX after COVID-19 booster showed a similar vaccine response to NIP. Patients who continued MTX demonstrated an impaired response indicating a potentially beneficial second booster vaccination. Our data also suggest that a 1 week MTX break is sufficient if the last administration of MTX occurs 1–3 days before vaccination.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results